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the Liver and Kidneys mediate 
clearance of cardiac troponin in  
the rat
Aida Muslimovic1,5, Vincent fridén1,5, Olav tenstad2, Karin Starnberg1, Susanne nyström1, 
emelie Wesén3, Elin K. esbjörner  3, Kristoffer Granholm1, Bertil Lindahl4 & 
ola Hammarsten1 ✉
Cardiac-specific troponins (cTn), troponin T (cTnT) and troponin I (cTnI) are diagnostic biomarkers when 
myocardial infarction is suspected. Despite its clinical importance it is still not known how cTn is cleared 
once it is released from damaged cardiac cells. The aim of this study was to examine the clearance of 
cTn in the rat. A cTn preparation from pig heart was labeled with fluorescent dye or fluorine 18 (18 F). The 
accumulation of the fluorescence signal using organ extracts, or the 18 F signal using positron emission 
tomography (PET) was examined after a tail vein injection. The endocytosis of fluorescently labeled cTn 
was studied using a mouse hepatoma cell line. Close to 99% of the cTnT and cTnI measured with clinical 
immunoassays were cleared from the circulation two hours after a tail vein injection. The fluorescence 
signal from the fluorescently labeled cTn preparation and the radioactivity from the 18F-labeled cTn 
preparation mainly accumulated in the liver and kidneys. The fluorescently labeled cTn preparation was 
efficiently endocytosed by mouse hepatoma cells. In conclusion, we find that the liver and the kidneys 
are responsible for the clearance of cTn from plasma in the rat.
Cardiac troponin (cTn) is a ternary complex consisting of three distinct subunits: cardiac troponin T (cTnT), 
cardiac troponin I (cTnI) and cardiac troponin C (cTnC). cTn binds thin filaments within the cardiomyocyte 
sarcomere and, with tropomyosin, makes muscular contraction dependent on calcium ions1. Both cTnT and 
cTnI are released into the circulation following cardiac damage2 and are the preferred cardiac biomarkers when 
myocardial infarction (MI) is suspected3. The use of cTn assays with low diagnostic cutoffs improve diagnostic 
accuracy for MI on the emergency departments4,5 and reduce hospital spending6. However, low diagnostic cutoffs 
have been accompanied by an accumulation of patients presenting with stable cTn levels above the accepted cutoff 
point without MI7,8. A third of older emergency department patients without MI on emergency departments have 
stable cTn elevations7, often for unknown reasons9, and are generally admitted to have their workup done6,10.
Even if MI can be excluded during the hospital stay, patients with stable cTn elevations still constitute a sig-
nificant health care problem, as a stable cTn elevation is a strong risk factor for the development of heart disease 
and death11–14.
The reason behind stable cTn elevations, where sample-to-sample variation is often 10%7 but can be as large 
as 40–50%15, is still unclear but is typically found at old age, in patients with decreased renal function or with 
comorbidities10. It is possible that, in addition to necrosis, cTnT and cTnI are also released from living cardiomy-
ocytes under ischemic stress16 and possibly from normal cardiomyocytes as well17. To understand the possible 
mechanisms that link stable cTn elevations to mortality, we need to know how cTn is released and cleared from 
the circulation10,18,19.
Surprisingly little is known about how cTn and other cardiac damage biomarkers, such as myoglobin, are 
cleared from the circulation. We know from our previous studies that cTnT and cTnI are cleared, in part, by 
the kidneys in rats and humans2,20. This could be a possible mechanism behind the stable cTn elevations in 
patients10,18,19 and rats21 with decreased kidney function. However, we also observe rapid clearance of cTnT and 
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cTnI in rats without renal function2,20. Apparently, there is also prominent extrarenal clearance of cTnT. To exam-
ine this in greater detail, we labeled a pig cTn complex and examined its clearance in the rat.
Methods
Animals. Male Wistar Kyoto rats (Harlan, Horst, The Netherlands) kept on standard fodder and with free 
access to water were used, unless otherwise stated. Anesthesia was induced and maintained by inhalation of 
isoflurane (Isobavet, Schering-Plough Animal Health, Buckinghamshire, UK, 4.5% induction and 3.2–3.9% 
maintenance), using the Univentor 400 anesthesia unit (AgnTho’s AB, Lidingö, Sweden). Anesthetized animals 
from injection experiments were euthanized after cardiac puncture, the hearts were dissected, rinsed in ice-cold 
PBS and sliced before freezing in liquid nitrogen for storage at −80°. Pig cardiac tissue was kindly provided by 
the Experimental Biomedicine (EBM) Core facility at Gothenburg University. The hearts were frozen in liquid 
nitrogen before storage at −80°. Both pig and rat hearts were used for preparations of cTn. All protocols and 
procedures involving animal experiments were in accordance with the guidelines in Directive 2010/63/EU of the 
European Parliament and of the Council on the protection of animals used for scientific purposes, and approved 
by the Regional Board for Ethical Review of research projects using animals in Gothenburg, appointed by the 
Swedish Ministry of Agriculture (Ethical Approval # 282–2012).
Purification of cTn complexes from pig and rat hearts. Both pig and rat hearts were used for purifi-
cation of cTn complexes. The amount of purified cTn obtained from rat hearts were limited. We therefore pre-
pared cTn from pig hearts that were available in substantially higher quantity. The cTn complex was essentially 
prepared as described22, using 700 g of frozen left ventricular cardiac pig tissue or 8 g of left ventricular cardiac 
rat tissue. The method below describes the cTn preparation from left ventricular cardiac pig tissue. However, the 
same procedure was used for the cardiac rat tissue that was used in the animal experiments. The diethyl ether 
powder was extracted twice for 1 h at a time with 400 mL phosphate-buffered saline, PBS, supplemented with 1 M 
NaCl, 1 mM CaCl2 and 1 mM Dithiothreitol, DTT, and protease inhibitors (1x cOmplete™, EDTA-free Protease 
Inhibitor Cocktail) (Roche). The extract was fractionated by ammonium sulphate precipitation as described. 
The 43.5% ammonium sulphate pellet was dissolved in a total of 110 mL Buffer P (0.1 M Tris-HCl pH 7.5, 0.1 M 
NaCl, 0.1 m M CaCl2), cleared by centrifugation and loaded on a 10 mL MMC column (GE Health Care) equil-
ibrated with Buffer P, washed with five column volumes of PBS supplemented with 1 M NaCl, followed by five 
column volumes of MQ water and finally developed with a 100 mL gradient using 50 mL 1 M NaCl, 0.1 M NaOH 
and 2 mL fractions were collected. The fractions were rapidly supplemented with 200 µl Tris-HCl, pH 7.5, 1 mM 
DTT to normalize the pH level, and stored at −20 °C. The final yield from the 700 g of heart tissue was 23 mg 
cTn, measured with the Bicinchoninic Acid Kit for Protein Determination (Sigma Aldrich) with bovine serum 
albumin as standard. The presence of cTnT and cTnI was confirmed using the Abbott STAT high-sensitivity cTnI 
assay and the Roche high-sensitivity cTnT assay. The presence of troponin C was inferred from overloaded SDS 
gels (Supplementary Fig. 2) but not directly detected or measured. cTnT and cTnI co-eluted just before bovine 
serum albumin (60 kDa) in size exclusion chromatography on a 40 mL Sephacryl S-300 as measured by the Roche 
hs-cTnT method on Cobas and the Abbott hs-cTnT method on Architect, indicating a molecular complex weight 
of roughly 80 kDa, as previously reported22,23. There was no elution of cTnI at 24 kDa in the chromatogram, indi-
cating that no free cTnI was present in the preparation (data not shown). In addition, the cTnT and cTnI levels 
were the same in blood samples collected from rats injected with the pig cTn preparation (Fig. 1), indicating that 
most of the cTnT and cTnI in the pig cTn preparation was present in a cTnT/cTnI complex. However, as it has 
been shown that monomeric cTnT and cTnT/cTnI/cTnC complexes co-elute on gel filtration chromatography23, 
we cannot determine whether all of the cTnT was present in a complex with cTnI. Indeed, some of the cTn prepa-
ration precipitated if kept at concentrations >2 g/L in low-salt buffers. SDS gel analysis of this precipitate indi-
cated that it was mostly cTnT that precipitated. cTnT is known to be unstable if not in a complex with cTnI22. For 
that reason, as described below, cTn preparations were kept in high-salt buffers until they were diluted > 100-fold 
in physiological buffers and centrifuged at 13 000xG to remove any precipitate before injection in animals.
Figure 1. Kinetics of cTnT and cTnI clearance after a jugular vein injection of purified pig cTn complex. Mean 
values from three rats. Error bars represent ±1 SD.
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The undiluted peak fractions with a protein concentration of 2 mg/mL had a tendency to precipitate at low 
ionic strength. For that reason, the cTn fractions were stored and labeled with Alexa-NHS dyes in buffers contain-
ing 1 M NaCl as described in next section. Prior to injection in the animals, the cTn preparations were diluted to 
100-fold lower concentrations (<0.1 mg/mL) and centrifuged at 13 000 G for five minutes to remove any precipi-
tate. However, at these lower concentrations, both the Alexa-labeled and unlabeled cTn preparations remained in 
solution with no evidence of precipitation.
Labeling of proteins with Alexa-N-hydroxysuccinimide (Alexa-NHS). Purified proteins were 
labeled with fluorescent dye using the Alexa-N-hydroxysuccinimide (Alexa-NHS) labeling procedure described 
below. Pig and rat cTn preparations were labeled with Alexa Fluor 488 NHS, horse myoglobin (Myo) with Alexa 
Fluor 350 NHS, and pig lactate dehydrogenase (LDH) (Sigma Aldrich) with Alexa Fluor 700 NHS. First, the pro-
tein preparations were desalted on a G50 column in Buffer L (0.2 M NaCO3 pH 8.3, 1 M NaCl) to remove all pos-
sible traces of Tris or other amine contaminants that could otherwise interfere with the N-hydroxysuccinimide 
(NHS) labeling. The proteins were concentrated on ultracentrifugation columns (Amicon) with the exclusion 
limit of 3 K to a protein concentration of 5–10 g/L. If lower protein concentrations were used, labeling with 
the Alexa-NHS reagents was inefficient. Alexa Fluor 488 NHS, Alexa Fluor 350 NHS or Alexa Fluor 700 NHS 
(Thermo Fisher Scientific) were added in fivefold molar excess and allowed to react in Buffer L for 3–24 hours at 
room temperature. The reaction mixture was then supplemented with an equal volume of 2 M Tris-HCl pH 7.5 to 
inactivate the NHS group, and purified away from the unreacted Alexa Fluor NHS dye on a G50 column in Buffer 
L. High molecular weight peak fractions containing the labeled proteins were concentrated on ultracentrifugation 
columns (Amicon) with the exclusion limit of 3 K and stored at −20 °C. The molar ratio of the Alexa Fluor NHS 
label to protein was 1–3 molecules per protein. When higher levels of labeling were used, the Alexa-labeled cTn 
preparations had a tendency to precipitate.
Intravenous injection of purified pig cTn complex and organ harvesting. Rats were anesthetized 
and reference blood samples were collected from all rats by tail snip, and tissue adhesive (Histoacryl®, B. Braun, 
Germany) was applied for wound closure. Intravenous (i.v.) injections of 300 µl protein cocktails containing cTn, 
Myo and LDH were administered via the right internal jugular vein in three rats. Blood samples (150 µl) were 
collected via the tail vein in conscious animals 10 min, 30 min, 60 min, 90 min, 3 h, 6 h and 24 h after the injection. 
Organs were harvested and frozen in liquid nitrogen before storage at −80 °C. Whole blood samples were left 
to stand for 60 min at room temperature, prior to centrifugation (Heraeus Fresco 17, Thermo Scientific GmbH, 
Germany) at 10 000 G for ten minutes at 4 °C. Serum was separated from the red blood cells and stored at −20 °C.
Organ extract and measurement of fluorescence. Frozen organ pieces varying in weight between 
0.11 g and 0.67 g from rats sacrificed after injection of fluorescent cTn, LDH and Myo were crushed using a small 
glass Dounce homogenizer (D8938, 2 mLSigma Aldrich, Sweden) at room temperature in an extraction buffer 
(phosphate buffer saline (PBS) supplemented with 10 mM EDTA and 10 mM DTT). The volume of extraction 
buffer was adjusted to limit the viscosity of the organ homogenate, which was a problem, especially for brain 
and quadriceps extracts, and the extracts were supplemented with 2% triton X-100. This was important in order 
to reduce turbidity in the later steps, especially in the brain and liver extracts. After extraction with gentle agita-
tion at +8 °C for 24 h, the extracts were centrifuged at 10 000 G for 30 minutes at +4 °C. The supernatants were 
collected. Clear extracts (250 µl) were transferred to 96-well plates and the fluorescence was measured with a 
FLUOROSCAN ASCENT FL using excitation/emission (ex/em) wavelengths of 355/460 nm for Alexa Fluor 350 
and ex/em wavelengths of 485/538 for Alexa Fluor 488. Alexa Fluor 700 was measured in a TECAN infinite M200 
microplate reader using ex/em wavelengths of 650/750 nm. All measurements were background-subtracted using 
organ extracts from untreated rats. The background-subtracted fluorescence signal per gram of extracted tissue 
was calculated and adjusted for total organ weight in the rat24–26; that is, the fluorescence signal per gram of organ 
was adjusted with the following factors, related to the organ’s relative proportion of the total body weight in rats: 
liver = 1, quadriceps muscle = 0.69, brain = 0.15, lungs = 0.11, small intestine = 0.67, kidneys = 0.21, spleen 
= 0.06, and heart = 0.08. Relative organ retention in liver and kidneys were different from all other organs by a 
two-sided t-test.
PET analysis of i.v. 18F-cTn injections in the rat. Pig cTn (2 mg/mL) was labeled with 18F for PET 
imaging by using an approach similar to that described by Olberg et al.27. 18F-cTn was then purified on a PD 
MidiTrap G-10 gravity column (GE Healthcare Bio-Sciences) using saline as eluent. The integrity of 18F-cTn was 
confirmed by size exclusion chromatography using a TSK gel G2000SWXL column (Tosoh Bioscience LLC) and a 
Thermo Scientific UltiMate 3000 Rapid Separation system. The elution pattern of 18F-cTn, as detected by an inline 
35 µl gamma D flow cell and a Radiomatic 625TR Flow Scintillation Analyzer (PerkinElmer Inc.), was similar to 
that of the unlabeled cTn complex, as detected by the UltiMate™ 3000 Diode Array Detector Flow Cell (2.5 µm).
A 30-minute dynamic PET scan (small-animal PET/CT, NanoScan PC PET/CT; Mediso Ltd, Budapest, 
Hungary) was performed during isoflurane anesthesia after a bolus injection of about 50 µl saline containing 
5 MbQ 18F-cTn in a lateral tail vein. The cannula was immediately flushed with 500 µl saline. The rat was then 
allowed to wake up and a final five-minute PET scan was performed under isoflurane anesthesia 180 minutes 
after a tracer injection. The following PET scan acquisition parameters were applied: Field of view, 9.6 cm in the 
axial direction and 10 cm in the transaxial direction, 1:5 coincidence mode and normal count rate mode. The 
body temperature was maintained at 37 °C throughout the whole procedure. Reconstruction of the PET data was 
performed with 3D OSEM and 1:3 coincidence mode, no filtering, attenuation correction (from a helical CT scan, 
70 kVp, 300 ms, 360 projections reconstructed using a Shepp Logan filter), decay correction and normalization of 
detectors. The images were analyzed using Interview fusion software (version 2.02.029.2010 BETA).
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Cells and sample preparation. Mouse hepatoma Hepa1c1c7 cells (Sigma Aldrich 95090613) were grown 
in a Minimum Essential Medium Eagle (MEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine 
and penicillin/streptomycin. The cells were detached (trypsin-EDTA 0.05%, five minutes) and passaged twice a 
week. For confocal microscopy imaging the cells were plated on 8-well chamber slides (ibi-treat 8-well µ-slides 
from ibidi, LRI instruments Inc.) with 50 000 cells/well one day before the experiment.
Endocytosis experiments and confocal microscopy. Cells were washed twice with serum-free medium 
and incubated at 4 °C or 37 °C for 30 min prior to protein addition. The cTn-Alexa Fluor 488 (10 mg/l), LDH-Alexa 
Fluor 488 (5 mg/L), Low-density lipoprotein (LDL) LDL-BODIPY®FL (2.5 mg/L) and Tropomyosin-Alexa Fluor 
488 (2.5 mg/L) were added to each microscopy slide and the incubations continued for two hours at 4 °C in order 
to inhibit endocytosis, or at 37 °C to promote endocytosis. The endocytosis inhibitor Dynasore hydrate (Sigma 
Aldrich) (50 µM) was added to the cells 30 minutes before addition of cTn-Alexa Fluor 488. As recommended, 
Dynasore hydrate treatment was performed in MEM without serum. The cells were washed twice with PBS, fixed 
with 4% paraformaldehyde, (PFA) in PBS for 15 min at 4 °C or room temperature, and washed once again with 
PBS. The nuclei were stained with 1 µM DAPI in PBS for five minutes, washed 1X with PBS and 2X with MQ 
water, and mounted with ibidi mounting medium (LRI Instruments Inc.). Confocal imaging was performed on 
a Nikon Eclipse Ti confocal microscope using a Nikon Apo 60X1.40 oil immersion objective with 405 nm and/or 
488 nm lasers for DAPI and Alexa Fluor 488 or BODIPY®FL, and the fluorescence was detected using the filter/
bandpass of 450 nm/50 nm and 525 nm/50 nm for the blue and green channel, respectively. Images were processed 
using the Fiji software (previous ImageJ, free software provided by the National Institutes of Health).
Laboratory analyses. Serum samples were stored at −20 °C before dilution in PBS supplemented with 
1 g/L bovine serum albumin (BSA) and analysis at the Clinical Chemistry Laboratory at Sahlgrenska University 
Hospital.
Analysis of cTnT was performed using the latest versions of the Roche hs-cTnT method on Cobas and the 
latest versions of the Abbott hs-cTnI method on Architect with coefficients of variation (CV) below 3.3% for TnT 
and below 6.9% for TnI at the troponin levels analyzed in this study18,28.
Results
Organ retention of fluorescently labeled cTn. Rats were co-injected in the tail vein with fluorescently 
labeled pig cTn labeled with Alexa Fluor 488, horse myoglobin (Myo) labeled with Alexa Fluor 350, and pig lac-
tate dehydrogenase (LDH) labeled with Alexa Fluor 700. Organs were harvested and frozen in pieces after 1.5 h, 
a time point when 99% of the cTnT and cTnI measured with high-sensitive clinical assays had been cleared from 
the blood (Fig. 1)20. The clearance kinetics of rat cTn and pig cTn were similar after an intravenous (i.v.) injection 
(Fig. 1 and Supplementary Fig. 1). Extracts were prepared from the harvested organs. The fluorescence signal 
in the organ extracts was measured and expressed as the relative fluorescence signal from each rat. The relative 
fluorescence signal from Alexa Fluor 488 was 72% in the liver, 24% in the kidneys and 2% in the spleen (Fig. 2). 
The organ distribution of Myo was similar to that of cTn, whereas LDH was retained mostly in the liver and only 
a small portion was retained in the kidneys, as previously reported29. The relative organ retention was similar in 
one rat where we performed label-switching and injected cTn labeled with Alexa Fluor 700 and LDH labeled with 
Alexa Fluor 488, indicating that the nature of the fluorescent dye was not important to the relative organ retention 
(Supplementary Fig. 3).
organ retention of 18F-labeled cTn by dynamic PET analysis. An 18F-labeled cTn preparation was 
injected in the tail vein in one anesthetized rat and the 18F signal was followed continuously by PET during a 
30-minute dynamic scan (Figs. 3–4). The 18F activity in the blood peaked after 15 seconds and then showed 
a rapid decline. The 18F-cTn accumulated in the liver, kidneys and the spleen before 18F-labeled material was 
excreted in the urine after a delay of about 15 minutes (Fig. 4A,B). 18F-cTn peaked in the liver after twelve minutes, 
whereas the 18F activity continued to increase in the kidney cortex throughout the clearance period of 30 minutes. 
At maximum liver retention, the relative organ content of 18F was 82% in the liver, 16% in the kidneys and 0.4% 
in the bladder (Fig. 4B). The continuous accumulation of 18F in the renal cortex suggests that 18F-cTn was filtered 
through the glomerular membrane and retained there during the clearance period of 30 minutes (Fig. 4C).
Assuming a total organ retention of 18F-cTn 0–5 minutes following an i.v. injection, the accumulation clear-
ance of cTn was calculated to be 0.70, 0.30 and 0.22 mL/min per cm3 tissue volume in the liver, kidney and spleen, 
respectively. Over extended periods, the clearance rates fell rapidly in the liver (t½ 17 min) and spleen (t½ 35 min), 
indicating rapid turnover in these organs (Fig. 4C). Using the 5-min clearances as representative of the organ 
uptake rate of 18F-cTn during the 30-minute clearance period, it could be predicted that the liver (volume 13.1 
cm3), the kidneys (volume 3.0 cm3) and the spleen (volume 0.8 cm3) accounted for 86%, 12% and 2%, respectively, 
of the total uptake of 18F-cTn (Fig. 4D).
cTn endocytosis by mouse hepatoma cells. To examine if cTn is internalized by transformed liver cells, 
we exposed mouse hepatoma cells (Hepa1c1c7) to fluorescently labeled cTn, in addition to LDH, low density 
lipoprotein (LDL) and tropomyosin. All proteins accumulated in the cytoplasm and the uptake was blocked by 
incubation at +4 °C that inhibits endocytosis (Fig. 5). The cytoplasmic accumulation of cTn was lower if the cells 
were preincubated with the endocytosis inhibitor Dynasore (Supplementary Fig. 5). Together, these data indicate 
that endocytosis was involved in the uptake of cTn by transformed mouse hepatoma cells.
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Discussion
This study was inspired by our findings that rats without kidney function still had prominent clearance of cTnT20. 
Here, we show that extrarenal clearance of cTn mainly occurs in the liver. Similar accumulation of cTn in the liver 
and kidneys was seen if cTn was labeled with 18F, Alexa Fluor 488 or Alexa Fluor 700, indicating that the nature 
of the label did not affect the organ retention of cTn30. We observed a fast uptake of fluorescently labeled cTn by 
mouse hepatoma cells in cell culture, which was blocked by incubation at 4 °C and by the endocytosis inhibitor 
Dynasore and therefore likely occurs by endocytosis.
Figure 2. Relative organ retention of fluorescently labeled proteins. cTn (a), lactate dehydrogenase (LDH) 
(b) and myoglobin (Myo) (c) 1.5 h after a tail vein injection. Mean values from three rats. Error bars represent 
±1 SD.
Figure 3. Organ retention of 18F-labeled pig cTn complex followed by PET. PET imaging 0.1, 30 or 180 minutes 
after a tail vein injection of 18F-labeled pig cTn complex.
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The liver removes unwanted proteins like LDH and desialylated serum proteins from plasma by 
receptor-mediated endocytosis31–34. Despite the obvious importance, surprisingly few studies have explored the 
clearance of cardiac damage biomarkers. Early studies indicate that myoglobin accumulated in the liver and 
spleen in patients who died from massive rhabdomyolysis35,36. Radioactive LDH is taken up by the liver in rats35–39. 
Although these studies never identified specific LDH receptors, the uptake is likely mediated by scavenger recep-
tors, a loosely defined group of receptors that are able to bind to a plethora of unwanted proteins and direct them 
to endocytosis and degradation in lysosomes40. Mice38,39 and humans29 with mutations in scavenger receptors 
develop stable LDH and creatine kinase elevations, indicating that impaired scavenger receptor clearance may 
result in stable elevations of cell damage biomarkers also in humans.
Our previous studies have established that cTnT is cleared, in part, by glomerular filtration20,21, but also that 
low kidney function can only explain a 2–3-fold elevation of cTnT. As many patients with stable cTnT elevation 
due to kidney failure sometimes have levels ten times higher than expected18, decreased kidney clearance cannot 
be the only mechanism behind stable cTn elevations in patients with impaired kidney function.
Figure 4. Distribution of 18F-cTn activity in the liver, spleen, kidneys and bladder urine, followed by PET. 
18F-cTn activity during the first 30 min after a tail vein injection. (a) Concentration per cm3 tissue (left y axis) 
or bladder urine (right y axis). (b) Total activity in organ or bladder (c) Organ accumulation clearance of 18F-
cTn calculated as organ concentration divided by the time-integrated plasma concentration of 18F activity for 
clearance periods of increasing length, from five to 30 minutes after an i.v. injection. (d) Total amount of 18F 
processed in organs calculated as the time-integrated product of five-minute organ accumulation clearance and 
plasma activity.
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The PET analysis in this study indicates that cTn was filtered through the glomerular membrane, known to 
allow passage of ovalbumin (43 kDa), which is similar in size to cTnT (37 kDa). Assuming a GFR of 1 mL/min per 
gram of kidney weight, the initial five-minute accumulation clearance of 18F-cTn in the renal cortex predicts a 
sieving coefficient of 18F-cTn of 0.341,42. If 18F is injected alone in the tail vein in rats, the 18F activity is concentrated 
to the central portion of the kidney, where the collecting ducts are assembled. This is because 18F is not absorbed 
by the proximal tubules. Therefore, the fast accumulation of 18F activity in the renal cortex after an 18F-cTn injec-
tion signifies that cTn was filtered and taken up in the proximal tubuli. This explains why only very low levels of 
cTnT are found in the urine in patients after an MI43.
It is known that receptor-mediated clearance becomes inefficient at low levels. This is well studied in the case 
of low-molecular weight heparin that is cleared by a fast, saturable receptor-mediated system at high levels and 
slow kidney-dependent clearance at low levels44. When heparin levels drop below the dissociation constant of the 
heparin receptors, receptor-mediated clearance becomes inefficient and only at these lower concentrations does 
the underlying, slower kidney clearance of low-molecular weight heparin become apparent44 (Fig. 6A).
This dual clearance model potentially explains why the clearance of cTn after a large MI is not very different 
in patients with or without kidney function45,46, whereas the low cTnT or cTnI levels found in patients with stable 
elevations are highly influenced by kidney function10,47,48.
Myoglobin (17 kDa), a protein small enough to be filtered through the glomerular membrane, is most likely 
also cleared by this dual system. Myoglobin accumulated in the liver and in the kidneys to a similar extent as cTn, 
whereas the much larger protein, LDH (150 kDa) preferentially accumulated in the liver, as previously shown29. 
Similar to cTnT, the clearance of myoglobin after an MI is not affected by kidney function49, whereas the low myo-
globin levels found in healthy subjects are strongly linked to kidney function50 (Fig. 6B).
We conclude that the preferential clearance of cTn via the liver potentially explains the clinical observations 
that cTn clearance after a large MI is not significantly affected by the patient’s kidney function46,51.
However, liver clearance is probably of little importance at the low cTn levels observed in most patients with 
stable cTn elevations. Scavenger receptors have binding constants, the ligand concentration where half of the 
receptors are occupied, in the nanomolar range (Kd for the LDL receptor, 18 nmol/L52). The cTnT and cTnI con-
centrations in patients with stable elevations are at least 1000 times lower (cTnT of 100 ng/L equals 2 pmol/L). 
Receptor occupancy in the liver is therefore expected to be less than 0.1% at these cTnT levels, likely making liver 
clearance inefficient. Therefore, stable cTn elevations below 100 ng/L are probably not due to inefficient liver 
clearance.
Compared to humans, rats and mice with experimental myocardial infarction, where the main coronary 
artery has been ligated, have similar ligation-to-peak time of 10 hours53 but the elimination of cTn is faster in 
rats and mice. In humans cTn elimination after non-perfused myocardial infarction often take weeks53, whereas 
cTn is often eliminated from the circulation within 3 days after coronary artery ligation in rats and mice54 likely 
due to the small necrotic volume in mice and rats. The kinetics of cTn after myocardial infarction is a reflection 
of both release of cTn from necrotic cardiac tissue and its subsequent clearance from the circulation. Our studies 
show that cTn is slowly released due to its tight binding to insoluble thin filaments in necrotic cardiac tissue and 
is subjected to a “trapping effect” that makes the elution of cTn very slow if the volume of the MI is large2,55. As we 
Figure 5. Uptake of fluorescently labeled proteins by mouse hepatoma cells. Confocal fluorescence microscopy 
imaging of the uptake of the Alexa Fluor 488-labeled cTn complex, lactate dehydrogenase (LDH) and 
tropomyosin and BODIPY®FL labeled low-density lipoprotein (LDL) by mouse hepatoma cells after 2 h 
incubation at 37 °C and at 4 °C. At 4 °C, the cellular uptake via endocytosis is expected to be blocked. Endocytic 
vesicles containing Alexa Fluor 488-labeled proteins appear as green dots. Cellular nuclei, blue, were stained 
with DAPI.
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show that cTn in the circulation has a half-life of less than one hour the kinetics of cTn after myocardial infarc-
tion20 is likely dominated by its slow and necrotic volume-dependent release and does not serve as a way to study 
cTn clearance. From our previous studies we know that cTn is cleared in the kidneys in humans2,20 but no other 
information concerning cTn clearance in humans exist.
This study has several limitations. It was performed in rats without myocardial damage. It is possible that the 
clearance of cTn, Myo and LDH could be different in humans undergoing myocardial infarction. Most exper-
iments were made using cTn prepared from pig heart tissue. Although the overall clearance of cTnT and cTnI 
was similar after injection of purified pig or rat cTn, there could be a species-specific effect in organ targeting. 
Finally, it is possible that the dominant form of cTnT and cTnI that is released from damaged cardiac tissue is 
different from the cTn preparations used in this study. For instance, studies indicate that most cTnT is full-length 
during the first hour after a large MI but after a few hours, most of the circulating cTnT is made up of degradation 
products56. In fact, we see that these cTnT degradation products are cleared more slowly compared to the pig cTn 
complex used in this study (Muslimovic, unpublished).
In conclusion, we find that the liver and the kidneys are responsible for the clearance of cTn from plasma in the rat.
Received: 18 November 2019; Accepted: 27 March 2020;
Published: xx xx xxxx
Figure 6. Model of cTn clearance. (a) Time course of the serum concentration of cTnT from Fig. 1 plotted on 
a log scale. There are two rates, an initial one with a half-life of 0.8 h that could be due to receptor-mediated 
endocytosis and degradation in the liver, and a subsequent rate with a half-life of 1.7 h that could be dominated 
by glomerular filtration49. (b) When cTn levels are high, such as after a myocardial infarction, cTn clearance 
mainly occurs by fast receptor-mediated uptake in the liver and the overall clearance of cTn would be minimally 
affected by slower kidney function but clear cTn with a similar half-life at both high and low levels. At the 
low levels of cTn observed in patients with heart failure, the levels are too low to be efficiently bound by liver 
receptors and slow cTn clearance via glomerular filtration becomes dominant.
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